Tesaro Inc. (NASDAQ:TSRO)’s share price reached a new 52-week high on Thursday . The company traded as high as $94.01 and last traded at $92.81, with a volume of 340,280 shares. The stock had previously closed at $92.33.

TSRO has been the subject of a number of analyst reports. Jefferies Group reissued a “buy” rating on shares of Tesaro in a report on Thursday, March 31st. Wedbush reiterated an “outperform” rating and issued a $72.00 target price on shares of Tesaro in a research note on Wednesday, April 6th. Mizuho reiterated a “buy” rating and issued a $67.00 target price on shares of Tesaro in a research note on Wednesday, April 6th. Leerink Swann reiterated a “buy” rating on shares of Tesaro in a research note on Monday, April 11th. Finally, FBR & Co started coverage on Tesaro in a research note on Wednesday, April 13th. They issued an “outperform” rating and a $65.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $76.50.

The company’s market capitalization is $4.21 billion. The firm has a 50 day moving average of $61.70 and a 200 day moving average of $46.69.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing the consensus estimate of ($1.69) by $0.53. The firm earned $0.31 million during the quarter, compared to analyst estimates of $2.48 million. During the same period in the previous year, the company posted ($1.30) earnings per share. On average, analysts expect that Tesaro Inc. will post ($7.16) EPS for the current fiscal year.

In other news, VP Edward C. English sold 7,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $40.75, for a total value of $285,250.00. Following the completion of the sale, the vice president now owns 3,500 shares in the company, valued at $142,625. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jeffrey H. Hanke sold 12,500 shares of the stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total value of $929,375.00. Following the completion of the sale, the vice president now owns 12,500 shares of the company’s stock, valued at approximately $929,375. The disclosure for this sale can be found here.

Several hedge funds have added to or reduced their stakes in TSRO. Jennison Associates LLC raised its stake in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock worth $49,100,000 after buying an additional 574,041 shares during the last quarter. Whittier Trust Co. raised its stake in Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 220 shares during the last quarter. BB Biotech AG raised its stake in Tesaro by 6.5% in the fourth quarter. BB Biotech AG now owns 1,229,582 shares of the biopharmaceutical company’s stock worth $64,332,000 after buying an additional 75,000 shares during the last quarter. Bank of Montreal Can raised its stake in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 19,320 shares during the last quarter.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.